Despite these findings, there is limited clinical evidence regarding the prognostic role of CD155 in individuals with NSCLC harboring the most common oncogenic alterations, such as Epidermal Growth Factor Receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.